Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population | Zendy

Ashley C. Bradford | Zendy; W. David Bradford | Zendy; Amanda J. Abraham | Zendy; Grace Bagwell Adams | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population

Author(s) -

Ashley C. Bradford,

W. David Bradford,

Amanda J. Abraham,

Grace Bagwell Adams

Publication year - 2018

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.0266

Subject(s) - medicine , medicaid , opioid , medical prescription , population , emergency medicine , environmental health , pharmacology , health care , receptor , economics , economic growth

Opioid-related mortality increased by 15.6% from 2014 to 2015 and increased almost 320% between 2000 and 2015. Recent research finds that the use of all pain medications (opioid and nonopioid collectively) decreases in Medicare Part D and Medicaid populations when states approve medical cannabis laws (MCLs). The association between MCLs and opioid prescriptions is not well understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research